Ads
related to: life expectancy for myeloma patients symptoms- Treatment Process
Discover The Treatment Info
& View Availability Here.
- Efficacy Data
Review Efficacy, Safety, & Clinical
Trial Data On The HCP Site.
- Treatment Centers
This RRMM Option Is Available
At Certified Treatment Centers.
- Trial Design
Review The Clinical Data For
This RRMM Treatment Option Here.
- Important Safety Info
HCPs: Review Important Safety Info
For This Option In Clinical Trials.
- Patient Eligibility
Discover If This RRMM Treatment
Option Is Right For Your Patients.
- Treatment Process
Search results
Results From The WOW.Com Content Network
Multiple myeloma (MM), also known as plasma cell myeloma and simply myeloma, is a cancer of plasma cells, a type of white blood cell that normally produces antibodies. [6] Often, no symptoms are noticed initially. [10] As it progresses, bone pain, anemia, renal insufficiency, and infections may occur. [10]
The goals of therapy are to control symptoms, improve quality of life, improve overall survival, and decrease progression to AML. The IPSS scoring system can help guide therapy for patients with MDS. [ 43 ] [ 44 ] In those with low risk MDS (designated by an IPSS score less than 3.5), no disease specific treatment has been found to be helpful ...
Treatment of patients with this POEMS syndrome variant who have evidence of bone lesions and/or myeloma proteins are the same as those for POEMS syndrome patients. In the absence of these features, treatment with rituximab , a monoclonal antibody preparation directed against B cells bearing the CD20 antigen, or siltuximab , a monoclonal ...
Secondary PCL (sPCL) is diagnosed in 1-4% of patients known to have had multiple myeloma for a median time of ~21 months. It is the terminal phase of these patients' myeloma disease. sPCL patients typically are highly symptomatic due to extensive disease with malignant plasma cell infiltrations in, and failures of, not only the bone marrow but also other organs.
Smouldering myeloma, however, is not a malignant disease. It is characterised as a pre-malignant disease that lacks symptoms but is associated with bone marrow biopsy showing the presence of an abnormal number of clonal myeloma cells, blood and/or urine containing a myeloma protein, and a significant risk of developing into a malignant disease. [2]
They are less likely than multiple myeloma patients to have lytic bone lesions. In several studies of patients with either form of plasma cell leukemia, the disease was associated with clonal IgG in 28% to 56% of cases, IgA in 4% to 7% of cases, and a light chain in 23% to 44% of cases; 0-12% of patients had no myeloma protein.